Use of commercially available sodium hyaluronate 0.18% eye drops for corneal epithelial healing in diabetic patients

Research output: Contribution to journalArticle

Abstract

Purpose: To evaluate the effect of topical sodium hyaluronate (SH) 0.18% treatment on corneal epithelial healing after epithelial debridement in pars plana vitrectomy in diabetic patients. Method: This is prospective and randomized clinical trial. Our study population included 30 eyes undergoing pars plana vitrectomy that required near total corneal debridement intra-operatively for surgical view. We compared the residual wound and wound healing rate in between 3 groups: 10 diabetic eyes (DMV) on topical SH 0.18%; 10 diabetic eyes (DMC) and 10 non-diabetic eyes (NDM) not treated with topical SH 0.18%. The corneal epithelial wound was measured at 12, 24, 36, 48, 60, 72 and 120 h after the vitrectomy surgery. Results: DMC group had corneal wounds that reepithelialization significantly more slowly than in NDM and DMV groups at 12, 24, 36 and 48 h (Mann–Whitney test p < 0.05). The epithelial healing rate was significantly faster at 12 h in NDM and DMV group (Mann–Whitney test p < 0.05). No differences in the residual epithelial wound and wound healing were detected in between NDM and DMV groups. The mean for epithelial closure in DMC group was delayed 87.6 ± 28.31 h, compared with DMV group (64.8 ± 21.31) and NDM group (56.4 ± 9.88). All groups were followed up 1 month beyond completed wound closure. No recurrent corneal epithelial wound, corneal melting or corneal neovascularization was noted. Conclusion: Diabetic patients on SH 0.18% four times daily for epithelial defect had similar corneal wounds healing rate as non-diabetics. This treatment significantly improved corneal wound healing and accelerated complete corneal wound resurfacing in diabetic patients.

Original languageEnglish
JournalInternational Ophthalmology
DOIs
Publication statusAccepted/In press - 1 Jan 2018

Fingerprint

Ophthalmic Solutions
Hyaluronic Acid
Wounds and Injuries
Wound Healing
Vitrectomy
Temazepam
Debridement
Corneal Neovascularization
Freezing
Randomized Controlled Trials
Therapeutics
Population

Keywords

  • Corneal epithelium
  • Diabetes
  • Hyaluronan
  • Sodium hyaluronate (SH)
  • Vitrectomy
  • Wound healing

ASJC Scopus subject areas

  • Ophthalmology

Cite this

@article{caa28f837040464d9b76c63010493cc9,
title = "Use of commercially available sodium hyaluronate 0.18{\%} eye drops for corneal epithelial healing in diabetic patients",
abstract = "Purpose: To evaluate the effect of topical sodium hyaluronate (SH) 0.18{\%} treatment on corneal epithelial healing after epithelial debridement in pars plana vitrectomy in diabetic patients. Method: This is prospective and randomized clinical trial. Our study population included 30 eyes undergoing pars plana vitrectomy that required near total corneal debridement intra-operatively for surgical view. We compared the residual wound and wound healing rate in between 3 groups: 10 diabetic eyes (DMV) on topical SH 0.18{\%}; 10 diabetic eyes (DMC) and 10 non-diabetic eyes (NDM) not treated with topical SH 0.18{\%}. The corneal epithelial wound was measured at 12, 24, 36, 48, 60, 72 and 120 h after the vitrectomy surgery. Results: DMC group had corneal wounds that reepithelialization significantly more slowly than in NDM and DMV groups at 12, 24, 36 and 48 h (Mann–Whitney test p < 0.05). The epithelial healing rate was significantly faster at 12 h in NDM and DMV group (Mann–Whitney test p < 0.05). No differences in the residual epithelial wound and wound healing were detected in between NDM and DMV groups. The mean for epithelial closure in DMC group was delayed 87.6 ± 28.31 h, compared with DMV group (64.8 ± 21.31) and NDM group (56.4 ± 9.88). All groups were followed up 1 month beyond completed wound closure. No recurrent corneal epithelial wound, corneal melting or corneal neovascularization was noted. Conclusion: Diabetic patients on SH 0.18{\%} four times daily for epithelial defect had similar corneal wounds healing rate as non-diabetics. This treatment significantly improved corneal wound healing and accelerated complete corneal wound resurfacing in diabetic patients.",
keywords = "Corneal epithelium, Diabetes, Hyaluronan, Sodium hyaluronate (SH), Vitrectomy, Wound healing",
author = "Ling, {Kiet Phang} and Bastion, {Mae-Lynn Catherine}",
year = "2018",
month = "1",
day = "1",
doi = "10.1007/s10792-018-1057-1",
language = "English",
journal = "International Ophthalmology",
issn = "0165-5701",
publisher = "Springer Netherlands",

}

TY - JOUR

T1 - Use of commercially available sodium hyaluronate 0.18% eye drops for corneal epithelial healing in diabetic patients

AU - Ling, Kiet Phang

AU - Bastion, Mae-Lynn Catherine

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Purpose: To evaluate the effect of topical sodium hyaluronate (SH) 0.18% treatment on corneal epithelial healing after epithelial debridement in pars plana vitrectomy in diabetic patients. Method: This is prospective and randomized clinical trial. Our study population included 30 eyes undergoing pars plana vitrectomy that required near total corneal debridement intra-operatively for surgical view. We compared the residual wound and wound healing rate in between 3 groups: 10 diabetic eyes (DMV) on topical SH 0.18%; 10 diabetic eyes (DMC) and 10 non-diabetic eyes (NDM) not treated with topical SH 0.18%. The corneal epithelial wound was measured at 12, 24, 36, 48, 60, 72 and 120 h after the vitrectomy surgery. Results: DMC group had corneal wounds that reepithelialization significantly more slowly than in NDM and DMV groups at 12, 24, 36 and 48 h (Mann–Whitney test p < 0.05). The epithelial healing rate was significantly faster at 12 h in NDM and DMV group (Mann–Whitney test p < 0.05). No differences in the residual epithelial wound and wound healing were detected in between NDM and DMV groups. The mean for epithelial closure in DMC group was delayed 87.6 ± 28.31 h, compared with DMV group (64.8 ± 21.31) and NDM group (56.4 ± 9.88). All groups were followed up 1 month beyond completed wound closure. No recurrent corneal epithelial wound, corneal melting or corneal neovascularization was noted. Conclusion: Diabetic patients on SH 0.18% four times daily for epithelial defect had similar corneal wounds healing rate as non-diabetics. This treatment significantly improved corneal wound healing and accelerated complete corneal wound resurfacing in diabetic patients.

AB - Purpose: To evaluate the effect of topical sodium hyaluronate (SH) 0.18% treatment on corneal epithelial healing after epithelial debridement in pars plana vitrectomy in diabetic patients. Method: This is prospective and randomized clinical trial. Our study population included 30 eyes undergoing pars plana vitrectomy that required near total corneal debridement intra-operatively for surgical view. We compared the residual wound and wound healing rate in between 3 groups: 10 diabetic eyes (DMV) on topical SH 0.18%; 10 diabetic eyes (DMC) and 10 non-diabetic eyes (NDM) not treated with topical SH 0.18%. The corneal epithelial wound was measured at 12, 24, 36, 48, 60, 72 and 120 h after the vitrectomy surgery. Results: DMC group had corneal wounds that reepithelialization significantly more slowly than in NDM and DMV groups at 12, 24, 36 and 48 h (Mann–Whitney test p < 0.05). The epithelial healing rate was significantly faster at 12 h in NDM and DMV group (Mann–Whitney test p < 0.05). No differences in the residual epithelial wound and wound healing were detected in between NDM and DMV groups. The mean for epithelial closure in DMC group was delayed 87.6 ± 28.31 h, compared with DMV group (64.8 ± 21.31) and NDM group (56.4 ± 9.88). All groups were followed up 1 month beyond completed wound closure. No recurrent corneal epithelial wound, corneal melting or corneal neovascularization was noted. Conclusion: Diabetic patients on SH 0.18% four times daily for epithelial defect had similar corneal wounds healing rate as non-diabetics. This treatment significantly improved corneal wound healing and accelerated complete corneal wound resurfacing in diabetic patients.

KW - Corneal epithelium

KW - Diabetes

KW - Hyaluronan

KW - Sodium hyaluronate (SH)

KW - Vitrectomy

KW - Wound healing

UR - http://www.scopus.com/inward/record.url?scp=85058118986&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85058118986&partnerID=8YFLogxK

U2 - 10.1007/s10792-018-1057-1

DO - 10.1007/s10792-018-1057-1

M3 - Article

AN - SCOPUS:85058118986

JO - International Ophthalmology

JF - International Ophthalmology

SN - 0165-5701

ER -